Long noncoding RNATUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta
Open Access
- 1 April 2024
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 115 (6) , 1910-1923
Abstract
Chemoresistance is a major cause of high mortality and poor survival in patients with ovarian cancer (OVCA). Understanding the mechanisms of chemoresistance is urgently required to develop effective therapeutic approaches to OVCA. Here, we show that expression of the long noncoding RNA, taurine upregulated gene 1 (TUG1), is markedly upregulated in samples from OVCA patients who developed resistance to primary platinum‐based therapy. Depletion of TUG1 increased sensitivity to cisplatin in the OVCA cell lines, SKOV3 and KURAMOCHI. Combination therapy of cisplatin with antisense oligonucleotides targeting TUG1 coupled with a drug delivery system effectively relieved the tumor burden in xenograft mouse models. Mechanistically, TUG1 acts as a competing endogenous RNA by downregulating miR‐4687‐3p and miR‐6088, both of which target DNA polymerase eta (POLH), an enzyme required for translesion DNA synthesis. Overexpression of POLH reversed the effect of TUG1 depletion on cisplatin‐induced cytotoxicity. Our data suggest that TUG1 upregulation allows OVCA to tolerate DNA damage via upregulation of POLH; this provides a strong rationale for targeting TUG1 to overcome cisplatin resistance in OVCA.Keywords
Funding Information
- Japan Agency for Medical Research and Development (23ama221204h, 23ck0106816h)
- Japan Society for the Promotion of Science (23H02747)
This publication has 51 references indexed in Scilit:
- DNA polymerase eta: A potential pharmacological target for cancer therapyJournal of Cellular Physiology, 2020
- Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancerCancer and Metastasis Reviews, 2020
- Expression of Concern: LncRNA TUG1 facilitates proliferation, invasion and stemness of ovarian cancer cell via miR‐186‐5p/ZEB1 axisCell Biochemistry and Function, 2020
- New strategies in ovarian cancer treatmentCancer, 2019
- Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancerBiomedicine & Pharmacotherapy, 2018
- Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenesJournal of Controlled Release, 2016
- Long Noncoding RNAs in Cancer PathwaysCancer Cell, 2016
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapyEuropean Journal of Pharmacology, 2009
- Translesion DNA Synthesis: Little Fingers Teach ToleranceCurrent Biology, 2004